The news is slowing down a little this week but the earnings continue for the large caps. So far as a group the earnings look good indicating solid fundamentals with the companies. The stocks have been reacting well and the sector has been moving higher and outperforming. This move higher raises the bar for the […]
June 24 Biotech Update
Nothing from the sector but the news is certainly the Brexit results. I am not well versed in all the nuances of what it means for the EU (no one is as there is now a two year negotiation process that will determine exactly what a Brexit means and how it will be done) but […]
April 21 Biotech Update
I think the best description of the sector is listless and uncertain. The price action has been mixed but more than anything else, there has been a significant lack of volume. No one wants to buy or sell biotechs and so they have been drifting with some good days and some bad days. We are […]
April 21 Biotech Update
A lot of news to cover and I want to get to it all, so maybe a little less detail and more topics today and I will circle back to the ideas over the next couple of days. In general, the sector is doing well with the deal flow news but I will talk more […]
April 17 Biotech Update
The sector is certainly weak to start the day and obviously this seems driven by the macro. It was not immediately clear to me the trigger for the selling. Was it renewed concerns over a Grexit? You would think by now investors are prepared for that potential and/or have been immunized by these repeated concerns. […]
Biotech Fund Action in the Run Up to ASCO
(This is a guest post by Emory Redd and the disclosures are his at the bottom as well. I also apologize for the table formatting. They actually look much better in word but I cannot figure out how to get them to work in wordpress. I was running out of time to get this out […]
April 22- Building Some Momentum
Everyone loves biotechs again. Has the bottom been put in? Perhaps but there was a lot of damage done to the sector, so I would remain selective on buys and not chase any of these early moves. That being said the coast is likely clear for the near term assuming that the large cap biotechs […]
January 7 Biotech Update: Good News for PCYC, EPZM, and FMI
I thought yesterday was going to start a run in biotechs but I was a day early. We had the broad market rally helping but the sector was pushed today by some positive news. Of course, every move higher in the sector is bemoaned as being too much making this one of the most hated […]
GenVec: hearing a comeback
On the verge of shutting down just a few months ago, Genvec (NASDAQ: GNVC) has recently had a comeback that might last for a few more years if its partnered hearing loss program yields good results in the clinic. As some background, in early 2010, Genvec was running higher in hopes that its gene therapy […]
November 20-EOD (or midday)
In terms of the sector it is more of the same with an inline to slight outperformance of the market writ large (when the market is treading water or going moderately higher). Despite this positive action I always get worried when I see reports that newsletter writer bearish sentiment is at multi-decade lows (often viewed […]
ASH 2013 Preview on Lymphoid Malignancies
This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking the biotech sector’s run the past 2 years. They are now within months of receiving approval for 2 indications where they could benefit patient lives […]
September 27- EOD
Not a particularly news rich day but the sector seemed to continue its momentum from yesterday and seemed to outperform the general market with a lot of green on a red day. 1. Well, it looks like JNJ is tossing another wrench in ECYT trials with more doxil supply problems. ECYT noted that they have […]
What to look for at ESMO 2013
Apropos to our post yesterday on upcoming medical conferences, we wanted to begin with some coverage of the European Cancer Congress 2013 (ECCO-ESMO). This conference takes place Friday, September 27th thru Tuesday, October 1st. Below we have some of the datasets and updates we are looking forward to seeing. ESMO planners also put out their, […]
August 22- EOD
A quiet day after the relatively interesting data release of INCY yesterday. Of course, it was forced quiet as the market broke for most of the day. There is really not much new to talk about outside of some positive sentiment in the sector (see the ONXX/AMGN discussion below). Outside of that it is more […]
Biotech and Pharma earnings preview
Starting after-hours on Tuesday, we’ll see a lot of biotech and pharmaceuticals earnings, guidance, and outlook on their current programs. With the market cooling off, companies will be under pressure to meet investor expectations. Next week a number of sector leaders will kick things off. We’ve listed the updates in chronological order. Amgen (Nasdaq: AMGN) […]
Heat Shock Protein 90 (HSP90) inhibitors: Back in the spotlight – Part 1
Heat Shock Protein 90 (HSP90) was originally proposed as a cancer drug target in the 1990s, though no drug in this class have ever successfully completed a randomized clinical trial, let alone achieve regulatory approval. Despite repeated setbacks, HSP90 inhibitors are poised to find a significant niche in the evolving cancer treatment landscape. We will […]
INCY – An Acquisition Target?
Today, any biotech company with a promising product may be considered a potential acquisition target. Incyte Pharmaceuticals can certainly be considered one such candidate. It is well known that Big Pharma has been struggling with a lack of productivity, exacerbated by expiring patents on their biggest drugs. Some companies have managed this better than others. […]
NVS – Novartis $440 Million Deal With Enanta- A Shift Away From Nucs
Novartis $440 Million Deal With Enanta- A Shift Away From Nucs The HCV landscape took another turn Tuesday with the announcement that Novartis (NYSE:NVS) had agreed to pay Enanta Pharmaceuticals $34 million upfront and up to $406 million in milestones for their Phase I ready NS5A inhibitor, EDP-239. If not for the HCV setting, this […]
